Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 12/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015335 | 1.00 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2CMETAP1 | |
| SCHEMBL1015336 | 1.00 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2CMETAP1 | |
| SCHEMBL27493624 | 0.87 | PNMT (0.41) | PNMTADRA2AADRA2BADRA2CMETAP1 | |
| SCHEMBL27595418 | 0.87 | PNMT (0.41) | PNMTADRA2AADRA2BADRA2CMETAP1 | |
| SCHEMBL24954520 | 0.76 | LMNA (0.41) | — | |
| SCHEMBL14380007 | 0.76 | DRD3 (0.46) | — | |
| SCHEMBL16245992 | 0.76 | ACHE (0.42) | METAP1 | |
| SCHEMBL1016046 | 0.76 | PNMT (0.41) | PNMTMETAP1 | |
| SCHEMBL1016672 | 0.76 | ACHE (0.41) | ADRA2AADRA2BADRA2C | |
| SCHEMBL9247844 | 0.76 | PNMT (0.42) | PNMTADRA2AADRA2BADRA2CMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101541760-B | Diaminocyclohexane and diaminocyclopentane derivatives | HOFFMAN-LA ROCHE LTD. (CH) | 2012-02-08 | — | — | CN | disclosed |
| EP-2089368-B1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7803816-B2 | MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7652053-B2 | Diaminocycloalkane MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| CN-101541760-A | Diaminocyclohexane and diaminocyclopentane derivatives | HOFFMANN LA ROCHE (CH) | 2009-09-23 | — | — | CN | disclosed |
| EP-2089368-A1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| EP-1934199-B1 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-04-22 | — | — | EP | disclosed |
| EP-1934199-A2 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| US-20080146636-A1 | For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol | ERICKSON SHAWN DAVID | 2008-06-19 | — | — | US | disclosed |
| WO-2008065021-A1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-05 | — | — | WO | disclosed |
| WO-2007039462-A2 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078165-A1 | MCH receptor antagonists | BERTHEL STEVEN J | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078165-A1 | MCH receptor antagonists | MCHR1, MCHR2, MC5R | PNMT 233/4885ADRA2A 84/4885ADRA2B 86/4885 |
| US-20080146636-A1 | For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol | GPR119, GIPR, EBP | PNMT 128/4885ADRA2A 34/4885ADRA2B 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.